US Patent 9,339,489: Scope, Claim Boundaries, and US Patent Landscape for 3D-Printed Rapidly Dispersible Levetiracetam
What does US 9,339,489 cover at claim level?
US Patent 9,339,489 claims a rapidly dispersible solid oral dosage form built from a three-dimensionally printed bound matrix dominated by levetiracetam (LEV) and designed to disperse in small volumes of water or saliva within tight time and hardness constraints. The core legal scope is anchored in (i) material composition, (ii) 3D-printed bound-matrix structure, and (iii) performance-defined biopharm targets across fasting and fed states.
Core claim spine (Claim 1)
Claim 1 is the broadest independent claim in the set you provided. It requires, in combination:
- Dosage form type: rapidly dispersible solid dosage form
- Structure/process: three-dimensionally printed bound matrix
- Composition (by wt of the matrix):
- LEV: 50-80% wt
- Disintegrant: 3-35% wt
- Binder: 0.5-20% wt
- Dispersion performance:
- Disperses in about 15 seconds or less
- In about 15 mL or less of water or saliva
- Mechanical property:
This combination is the gating element for validity and infringement analysis: falling outside any one constraint breaks Claim 1.
Dependent claims that tighten scope (2-21) and key “fallback” positions
The dependent claims are not merely optional add-ons; several define measurable thresholds that create distinct infringement “landing zones.”
Antioxidant package
- Claim 2 adds antioxidant to the bound matrix.
- Claim 3 quantifies antioxidant: 0.005 to ~5.0% wt.
Oxidative stability
- Claim 4 limits oxidative degradant: 0.1% or less after 21°C for 6 months at 75% RH.
Biopharm exposure targets (Cmax/AUC/Tmax)
The claims hardwire pharmacokinetic outcomes, stratified by fasted and fed dosing.
Fed/Fasted ratios (Claims 11-12)
- Claim 11:
- Cmax fed/fasted ratio 0.55-0.74
- Tmax fed/fasted ratio 5-21
- Claim 12:
- AUC0-t fed/fasted ratio 0.89-0.98
- AUCinf fed/fasted ratio 0.89-0.99
Equivalence to KEPPRA® (Claim 13)
- Claim 13 states equivalence in rate and extent of absorption to KEPPRA® tablet (NDA N021035) by meeting Cmax and AUC metrics.
Extensive formulation/structure carve-outs (Claim 14)
Claim 14 is a highly constrained package that still hangs off Claim 1. It requires multiple additional facts simultaneously:
- Non-compressed:
- dosage form not compressed
- bound matrix not compressed
- exterior harder than interior
- Dissolution vs dispersion sequencing:
- dissolution time slower than dispersion time in aqueous fluid
- bound matrix disperses in ~10 sec or less in small volume
- Conversion/dissolution extent:
- at least 75% LEV dissolves in ~2 minutes or less
- Solid state forms:
- LEV form includes hydrate, hemi-hydrate, crystalline, amorphous, anhydrate, or combinations
- Moisture window:
- not more than 10% wt and not less 0.1% moisture by loss on drying at 120°C
- Uniform hardness profile
- Optional other medicaments
- Glycerin requirement options:
- includes glycerin
- and optionally glycerin amount 0.05%-3% wt
- USP paddle dissolution end-point:
- ≥95% LEV dissolved in ≤5 min in 900 mL at pH 1.2/4.5/6.8, 50 RPM
Broader optional ingredients (Claims 15-16)
Manufacturing and ingredient exemplars
- Claim 17: prepared by 3D printing.
- Claim 18: ingredient ranges (final dosage form wt):
- LEV 60-70%
- disintegrant 20-25%
- binder 10-15%
- sweetener 0.5-2%
- glidant 0.1-1.5%
- glycerin 0.1-5%
- surfactant 0.05-1.5%
- flavor 0-0.5%
- Claim 19: includes antioxidant (dependent on Claim 18).
- Claim 20: further technical process/form constraints:
- hardness 2-6 kp or 3-9 kp
- dispersion ≤10 sec in 15 mL
- binder introduced by printing fluid or bulk powder
- LEV mass 250-1000 mg
- 15-50 printed incremental layers
- each layer thickness 0.008-0.012 inches
- or matrix porous and non-compressed
- Claim 21: preservative-free.
Method claim (Claim 22)
- Treat disease responsive to LEV using the dosage form of Claim 1.
- Dosing: 1-3 times daily for a treatment period.
Hardness band (Claim 23)
- hardness 2-6 kp or 3-9 kp.
Product copies (Claims 24-26)
- Claim 24 duplicates a subset: fed/fasted AUC fed/fasted ratio constraints plus dispersion/hardness and composition.
- Claim 25 states porous and non-compressed additional limit.
- Claim 26 states LEV mass 250-1000 mg additional limit.
What is “most infringement-relevant”?
The infringement center of gravity is the Claim 1 matrix:
- 3D-printed bound matrix
- LEV 50-80%, disintegrant 3-35%, binder 0.5-20%
- Disperse ≤15 sec in ≤15 mL water/saliva
- Hardness ≥2 kp
Any product positioned as a rapidly dispersible LEV solid using 3D printing must also match the hardness and dispersion-in-small-volume metric, not just general “fast disintegration.”
The dependent biopharm claims (5-12) create an additional risk layer for products where PK is designed and can be measured to fall into the specified bands.
How do claims differ from one another (scope map)?
Below is a claim-scope map focused on the major “axes” that create distinct legal boundaries.
Axis A: Composition constraints
- Base: LEV 50-80%, disintegrant 3-35%, binder 0.5-20% (Claim 1)
- Example composition bands (Claim 18):
- LEV 60-70%
- disintegrant 20-25%
- binder 10-15%
- adds sweetener/glidant/glycerin/surfactant/flavor
Axis B: Physical form and mechanical behavior
- Hardness:
- minimum ≥2 kp (Claim 1)
- additional windows (Claim 20/23): 2-6 kp or 3-9 kp
- Structural state:
- explicitly non-compressed and porous appears in multiple later claims (Claim 14, 15, 25)
- Dispersion vs dissolution sequence:
- Claim 14 requires dissolution time slower than dispersion time and then specific dissolution endpoints (USP paddle)
Axis C: Small-volume dispersion/time
- Claim 1: disperses in ~15 sec or less in ~15 mL or less
- Claim 14: disperses in ~10 sec or less and provides 75% dissolves in 2 min
- Claim 15: disperses <15 sec in 10 mL
Axis D: Stability/quality
- Claim 4: oxidative degradant ≤0.1% after stress storage conditions
Axis E: PK outcomes and equivalence
- Claim 5-7: fasted Cmax/Tmax/AUC windows by dose
- Claim 8-10: fed Cmax/Tmax/AUC windows by dose
- Claim 11-12: fed/fasted ratios for Cmax, Tmax, and AUC
- Claim 13: equivalence to KEPPRA® tablet per NDA N021035
What does the current claim set imply for design-around?
This patent is structured so that design-around typically fails when a competitor cannot avoid the combined performance-mechanics-material envelope.
Likely design-around pathways (conceptual, claim-driven)
- Avoid the hardness + dispersion-in-small-volume target simultaneously (Claim 1): many fast-disintegrating approaches lose hardness or do not meet dispersion in ≤15 mL.
- Avoid binder/disintegrant loading ratios: Claim 1 enforces narrow ranges for both disintegrant and binder.
- Avoid three-dimensional printed bound matrix: if not 3D printed, Claim 1 is harder to reach. But note Claim 14/15/17 anchor the 3D printing concept.
- Avoid matching fed/fasted PK bands: even if formulation matches Claim 1, falling outside dependent PK windows can neutralize Claims 5-12, 24.
- Avoid non-compressed porous matrix with specific dissolution schedule: targets Claim 14/15/25.
Patent landscape: where does US 9,339,489 sit relative to the levetiracetam solid-dose universe?
US 9,339,489 is a formulation/dosage-form patent that combines:
1) 3D-printed bound matrices, and
2) rapid dispersion in saliva/water in small volumes, and
3) LEV-specific composition loading, and
4) measured hardness, and
5) optional oxidative stability constraints, and
6) PK windows (dependent).
Within the levetiracetam landscape, the key competitive reference point is KEPPRA® (NDA N021035) and its established IR tablet absorption profile used by Claim 13 as an equivalence benchmark. The claim set also implies that ordinary generic LEV tablets do not automatically meet the rapid dispersion in small volumes and hardness conditions, even if they match PK.
Why KEPPRA® matters legally (Claim 13 tether)
Claim 13 states equivalence to KEPPRA® by Cmax/AUC measures. That means:
- If a competitor’s product has similar absorption metrics but differs materially in dispersion/hardness, Claim 13 is avoidable.
- If a competitor’s product matches Claim 1 dispersion/hardness and also matches PK metrics, then dependent claims increase exposure.
Scope in litigation terms: “product-by-process” and performance claims
Although Claim 1 is a dosage-form claim, it contains process-type limitations (“three-dimensionally printed bound matrix”) and product performance limitations (dispersion time/volume, hardness). That combination typically expands evidentiary points in enforcement:
- manufacturing proof (printing fluid or bulk binder incorporation is specified in Claim 20),
- physical property measurement (hardness kp),
- dispersion test design (volume 15 mL, water/saliva, ~15 sec),
- oxidative stability assay conditions,
- fed/fasted PK study outcomes.
Key takeaways
- US 9,339,489 claim scope is anchored on a 3D-printed bound matrix of LEV 50-80%, disintegrant 3-35%, binder 0.5-20%, with hardness ≥2 kp and rapid dispersion ≤15 sec in ≤15 mL of water or saliva (Claim 1).
- Dependent claims significantly narrow the field through antioxidant loading, oxidative stability (≤0.1% degradant), and measurable fed/fasted PK bands (Claims 5-12, 24).
- The most enforceable “core” elements for competitors are not generic “fast dissolution,” but the specific pairing of small-volume dispersion time with matrix hardness and 3D printing.
- The landscape risk is highest for any product that aims to replicate both the rapid dispersion mechanics and the specified PK equivalence/range.
FAQs
1) Is US 9,339,489 limited to specific levetiracetam polymorphs?
No single polymorph is required in Claim 1. Claim 14 adds an LEV form selection that includes hydrate, hemi-hydrate, crystalline, amorphous, anhydrate, or combinations.
2) What is the dispersion test condition that drives Claim 1?
Claim 1 ties dispersion to about 15 seconds or less in about 15 mL or less of water or saliva.
3) Does the patent require compression?
No. Claim 1 does not require non-compression, but later claims explicitly require it (e.g., Claim 14 requires the dosage form and bound matrix are not compressed; Claim 15 and 25 also require porous and non-compressed).
4) What do the fed/fasted claims add beyond Claim 1?
They create additional limitations on Cmax, Tmax, and AUC ranges by dose, plus fed/fasted ratio windows, which can be used to attack or confirm infringement even when dispersion meets Claim 1.
5) What is the structural definition of the “bound matrix”?
The claims define a three-dimensionally printed bound matrix comprising LEV particles bound by a binder, with disintegrant included to drive rapid dispersion.
References
[1] United States Patent and Trademark Office. US Patent 9,339,489. https://patentscope.wipo.int/ (search USPTO patent number 9,339,489 for the official record; claim set and bibliographic data sourced from the patent document as provided).
[2] FDA. KEPPRA® NDA N021035 (levetiracetam). https://www.accessdata.fda.gov/ (NDA listing and product reference used for the KEPPRA benchmark cited in Claim 13).
